Metsera falls after Pfizer files a second lawsuit against co and Novo

Shares of drug developer Metsera MTSR.O fall 3.1% to $61.13 after Pfizer PFE.N files a second lawsuit against co and Novo Nordisk NOVOb.CO

Co's shares hit a record high last week following counter-bid from Novo Nordisk after Pfizer already locked in a deal with it valued at about $7.3 bln

PFE accusesn MTSR of anticompetitive conduct

PFE says it is taking the action to "enforce and preserve its rights under the merger agreement"

PFE filed a lawsuit against MTSR on Friday for breaching the agreement, which the drug developer had disagreed with

PFE received approval from the U.S. Federal Trade Commission on Friday for proposed buyout of MTSR

MTSR shares have gained more than double after listing in January